News - Impax Laboratories, Inflammatory diseases

Filter

Popular Filters

1 to 25 of 83 results

Impax Pharma resubmits NDA for Rytary

Impax Pharma resubmits NDA for Rytary

11-04-2014

Impax Laboratories’ branded products division has resubmitted the New Drug Application for Rytary (carbidopa…

Impax LaboratoriesNeurologicalNorth AmericaPharmaceuticalRegulationRytaryUSA

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Insmed’s mixed results from Ph II trial for treatment resistant NTM lung infections

27-03-2014

US-based Insmed has reported mixed results from its Phase II clinical trial of Arikayce, for the treatment…

Inflammatory diseasesInsmedPharmaceuticalRegulationRespiratory and PulmonaryUSA

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

NovaSAID partners with Cadila to develop inflammation and pain therapies

10-01-2014

Swedish research based company NovaSAID (a Karolinska Development portfolio firm) and Cadila Pharmaceuticals,…

Cadila PharmaceuticalsInflammatory diseasesNeurologicalNovaSAIDPharmaceuticalResearch

Impax and DURECT in $63 million deal for Eladur pain patch

07-01-2014

US specialty drugmaker Impax Laboratories has entered into an agreement with fellow USA-based DURECT…

DurectEladurGlobalImpax LaboratoriesLicensingNeurologicalPharmaceutical

Shield Therapeutics’ ST10 delivers robust results in AEGIS Ph III program

07-01-2014

Independent UK pharma firm Shield Therapeutics has announces strongly positive top-line data from the…

HematologyInflammatory diseasesPharmaceuticalResearchShield TherapeuticsST10

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

Patent expiries will push Parkinson’s drug market lower by 2019

17-12-2013

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s disease (PD)…

GlobalImpax LaboratoriesMarkets & MarketingNeurologicalNewron PharmaPatentsPharmaceuticalpimavanserinRytarysafinamide

Ampio Pharma takes spin-out route on failure to find Zertane partner

Ampio Pharma takes spin-out route on failure to find Zertane partner

16-12-2013

US drug developer Ampio Pharmaceuticals announced that it has spun off its sexual dysfunction business…

Ampio PharmaceuticalsAmpionInflammatory diseasesMen's HealthMergers & AcquisitionsPharmaceuticalProductionVyrix PharmaceuticalsZertane

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development

05-11-2013

At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Actavis challenges Rayos patent

28-08-2013

US generic drugmaker Actavis (NYSE: ACT) has confirmed filing an Abbreviated New Drug Application with…

ActavisGenericsHorizon PharmaImmunologicalsInflammatory diseasesPatentsRayos

Novartis gains breakthrough therapy designation for sIBM drug from US FDA

20-08-2013

Swiss drug major Novartis (NOVN: VX) has gained US Food and Drug Administration breakthrough therapy…

bimagrumabInflammatory diseasesNorth AmericaNovartisPharmaceuticalRegulation

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Teijin and Amgen join forces on autoimmune disease research

31-07-2013

Japan's Teijin Pharma, the core company of the Teijin Group's (TSE: 3401) health care business, has entered…

AmgenBiotechnologyImmunologicalsInflammatory diseasesLicensingPharmaceuticalResearchTeijin

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

Generic versions of Trilipix debut in USA; Mylan sued by UCB

16-07-2013

Impax Laboratories (Nasdaq: IPXL) today announced yesterday (July 15) that it is commencing shipment…

AbbVieCardio-vascularGenericsImpax LaboratoriesLegalMarkets & MarketingMylan LaboratoriesNeurologicalNorth AmericaPatentsTripilixUCBVimpat

1 to 25 of 83 results

Back to top